Glassman Wealth Services’s Heron Therapeutics HRTX Stock Holding History

Glassman Wealth Services’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-35	Closed	–	–	1806
2022 Q2	$0	Buy	+35	New	+$141	﹤0.01%	1814
2021 Q4	–	Sell	-162	Closed	-$2K	–	1752
2021 Q3	$2K	Hold	162	–	–	﹤0.01%	1174
2021 Q2	$3K	Hold	162	–	–	﹤0.01%	1058
2021 Q1	$3K	Hold	162	–	–	﹤0.01%	997
2020 Q4	$3K	Hold	162	–	–	﹤0.01%	978
2020 Q3	$2K	Hold	162	–	–	﹤0.01%	999
2020 Q2	$2K	Hold	162	–	–	﹤0.01%	861
2020 Q1	$2K	Sell	162 -1,000	-86%	-$18.8K	﹤0.01%	709
2019 Q4	$27K	Buy	1,162 +1,000	+617%	+$22.1K	0.01%	335
2019 Q3	$3K	Sell	162 -20	-11%	-$368	﹤0.01%	625
2019 Q2	$3K	Buy	182 +20	+12%	+$400	﹤0.01%	642
2019 Q1	$4K	Hold	162	–	–	﹤0.01%	581
2018 Q4	$4K	Buy	+162	New	+$4.45K	﹤0.01%	459

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Glassman Wealth Services's HRTX Position: Q3 2022 in Review

Glassman Wealth Services sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 35 shares.

Glassman Wealth Services first reported a position in HRTX in Q4 2018 and held it in 13 quarters. The position peaked at $27K in Q4 2019. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

Glassman Wealth Services reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
Glassman Wealth Services sold 35 Heron Therapeutics shares in Q3 2022.
Glassman Wealth Services first reported a position in Heron Therapeutics in Q4 2018 and held it in 13 quarters.
Glassman Wealth Services's Heron Therapeutics position peaked at $27K in Q4 2019.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on Glassman Wealth Services's 13F filing for Q3 2022, filed 9 Nov 2022.